Pfizer bets on Arena's promising bowel disease treatment in $6.7 billion deal
Reuters
Published Dec 13, 2021 06:33AM ET
Updated Dec 13, 2021 10:56AM ET
By Mrinalika Roy and Leroy Leo
(Reuters) - Pfizer Inc (NYSE:PFE) said on Monday it would buy drug developer Arena Pharmaceuticals Inc for $6.7 billion in cash, to add a promising treatment candidate that targets diseases affecting the stomach and intestine.
The $100 per share offer is double the last closing price of Arena's stock, which surged 83.7% to $91.92 in early trading.
This is the latest deal Pfizer has struck this year to expand its treatment pipeline. The company last month acquired immuno-oncology company Trillium Therapeutics (NASDAQ:TRIL) Inc for about $2.22 billion to strengthen its arsenal of blood cancer therapies.
Monday's deal will help Pfizer gain access to Arena's lead candidate, etrasimod, which is being tested in a late-stage trial in ulcerative colitis, as well as in a mid-to-late stage study in Crohn's disease, both types of inflammatory bowel diseases that cause ulcers in the digestive tract.
Inflammatory bowel disease is a $20 billion market globally, making it a lucrative target for drugmakers.
Earlier this year, the U.S. Food & Drug Administration approved Bristol Myers (NYSE:BMY) Squibb's Zeposia for ulcerative colitis.
Jones Trading analyst Prakhar Agrawal said etrasimod produced strong data in a mid-stage trial which looked better than Zeposia and has other convenience benefits like dose adjustments, early onset of relief that could help differentiate from rivals.
"(Etrasimod) has the potential to be best-in-class drug in these indications...could be a multi-billion blockbuster drug in just Crohn's and ulcerative colitis and we forecast risk adjusted revenue of $3.8 billion."
Pfizer is also developing a treatment for ulcerative colitis, a chronic and inflammatory bowel disease that affects 3 million people in the United States. The candidate is currently in a mid-stage study, which is expected to be completed by the end of next year.
The deal is expected to close in the first half of 2022.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.